CNB-001

CNB-001 is a **synthetic pyrazole derivative of curcumin** developed to improve the biological and pharmacokinetic limitations of curcumin. It is designed as a neuroprotective and neurotrophic agent and shows **broad neuroprotective, anti-inflammatory, and antioxidant effects** in multiple preclinical models. It inhibits neuroinflammatory signaling in microglia by reducing the activity of nuclear factor-κB (NF-κB) and p38 mitogen-activated protein kinase (MAPK), leading to decreased nitric oxide (NO) and inducible nitric oxide synthase (iNOS) expression[1]. CNB-001 also enhances dopamine neuron survival, preserves monoamine transporter expression, improves mitochondrial protection, and ameliorates behavioral deficits in rodent models of neurodegenerative diseases such as **Alzheimer's and Parkinson's disease**[3][5][8]. It modulates PI3K-Akt signaling, maintains ATP levels, and affects calcium-calmodulin-dependent protein kinase IIa. Its **primary potential indications** include Alzheimer's disease, Parkinson's disease, traumatic brain injury, stroke, and lung inflammation. Developed by researchers at the Salk Institute, CNB-001 is orally bioavailable, crosses the blood-brain barrier, and has demonstrated favorable safety and tolerability in animal studies[5][7].

Other names

pyrazole curcumin derivative